Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Anti IL-12 monoclonal antibody/ABT-874 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| 1 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, up to 12 weeks, 200 mg every week for 12 weeks |
| 2 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg QOW for 12 weeks |
| 3 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 100 mg QOW in 12 weeks |
| 4 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 4 doses in 12 weeks |
| 5 | ACTIVE_COMPARATOR | Anti IL-12 monoclonal antibody/ABT-874, 200 mg times 1 dose in 12 weeks |
| 6 | PLACEBO_COMPARATOR | placebo, 12 doses |
| Name | Type | Description |
|---|---|---|
| Anti IL-12 monoclonal antibody/ABT-874 | DRUG | Please see Arm Description for intervention description and details. |
| placebo | DRUG | 12 doses |
Inclusion Criteria: * Subject was age 18 or older and in good health (Investigator discretion) with a recent stable medical history. * Subject had a clinical diagnosis of psoriasis for at least 6 months, and had moderate to severe plaque psoriasis Exclusion Criteria: * Subject had previously rece...
Top 12 of 13 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Johnson & Johnson | JNJ | 11 | PHASE3 | JNJ-77242113, Ustekinumab, Guselkumab |
| Bristol-Myers Squibb Company | BMY | 14 | PHASE3 | Deucravacitinib |
| AbbVie, Inc. | ABBV | 5 | PHASE3 | Risankizumab |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 3 | PHASE3 | Zasocitinib |
| Alumis Inc. | ALMS | 2 | PHASE3 | Envudeucitinib |
| Oruka Therapeutics, Inc. | ORKA | 4 | PHASE2 | ORKA-002, ORKA-001 |
| Can-Fite Biopharma Ltd | CANF | 1 | PHASE3 | Piclidenoson |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE3 | Ponesimod |
| Novartis AG Sponsored ADR | NVS | 4 | - | Secukinumab |
| Bausch Health Companies Inc. | BHC | 2 | - | Brodalumab |
| Merck & Co., Inc. | MRK | 1 | PHASE1 | MK-8644 |
Anti IL-12 monoclonal antibody/ABT-874 is being studied for the treatment of moderate to severe chronic plaque psoriasis, a skin condition in the dermatology therapeutic area. It is an investigational monoclonal antibody developed by AbbVie Inc. and has been evaluated in a Phase 2 clinical trial.
Anti IL-12 monoclonal antibody/ABT-874 targets interleukin-12, also known as IL-12. By binding to IL-12, this monoclonal antibody is designed to interfere with the inflammatory signaling pathway implicated in psoriasis. The drug is an antibody-based therapy being developed for immune-mediated skin disease.
Anti IL-12 monoclonal antibody/ABT-874 is developed by AbbVie Inc., which trades on the New York Stock Exchange under the ticker ABBV. AbbVie is the sponsor of the clinical program evaluating this monoclonal antibody in psoriasis.
Anti IL-12 monoclonal antibody/ABT-874 is in Phase 2 clinical development. It is an investigational therapy and has not been approved by the FDA. The Phase 2 program has been completed, with one trial conducted in the United States and Canada.
Anti IL-12 monoclonal antibody/ABT-874 has been evaluated in one completed Phase 2 trial, NCT00292396, titled Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis. The trial enrolled 180 participants, was randomized, double-blind, and placebo-controlled, and included adults aged 18 years and older.
Yes, anti IL-12 monoclonal antibody/ABT-874 is also known as ABT-874. The two names refer to the same investigational monoclonal antibody developed by AbbVie Inc. for moderate to severe chronic plaque psoriasis.